Ramiah Investment Group Incyte Corp Transaction History

Ramiah Investment Group

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 10, 2025	SELL	$52.16 - $64.19 $535,891 - $659,488	-10,274 Closed	0 $0
Q3 2023 Feb 10, 2025	SELL	$57.77 - $65.93 $124,609 - $142,211	-2,157 Reduced 17.35%	10,274 $594 Million
Q2 2023 Feb 10, 2025	SELL	$60.95 - $75.51 $1,036 - $1,283	-17 Reduced 0.14%	12,431 $774 Million
Q1 2023 Feb 11, 2025	BUY	$70.23 - $86.01 $90,947 - $111,382	1,295 Added 11.61%	12,448 $900 Million
Q4 2022 Feb 10, 2025	BUY	$67.18 - $84.11 $50,989 - $63,839	759 Added 7.3%	11,153 $896 Million
Q3 2022 Feb 10, 2025	BUY	$66.18 - $82.86 $687,874 - $861,246	10,394 New	10,394 $693 Million

674

187M

712K

547K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.2B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Ramiah Investment Group, based on Form 13F filings with the SEC.

Stay updated on Ramiah Investment Group with notifications on news.